Improved Diagnostic Test Benefits Children With Acute Myeloid Leukemia, St. Jude Children's Research Hospital Study

9/11/2012 8:02:19 AM

Early treatment response is a powerful predictor of long-term outcome for young patients with acute myeloid leukemia (AML). The information can help physicians decide whether a more intensive approach is needed. Research led by St. Jude Children's Research Hospital investigators has identified the best test for measuring that response and guiding therapy. The method uses a laboratory technique called flow cytometry, which makes it possible to identify a single cancer cell in 1,000 normal cells that remain in patient bone marrow after the initial intensive weeks of chemotherapy. St. Jude investigators were instrumental in developing the test for identifying very low levels of cancer called minimal residual disease.

Read at ScienceDaily

Read at News Release

Read at Newswise

Read Article at

Related Companies

News Categories

• ScienceDaily

• News Release

• Newswise

• St. Jude Children's Research Hospital

• Diagnostics

• Medical Dev. & Diag. - Research